Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003328401 | SCV001244362 | pathogenic | CDH1-related diffuse gastric and lobular breast cancer syndrome | 2023-08-04 | reviewed by expert panel | curation | The CDH1 c.467G>A (p.Trp156Ter) variant is predicted to result in a premature stop codon that leads to nonsense mediate decay (PVS1 and PM5_supporting). The variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). Therefore, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (CDH1 VCEP specifications version 3.1): PVS1, PM2_supporting, PM5_supporting. |
Labcorp Genetics |
RCV000525870 | SCV000637830 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2017-03-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in CDH1 are known to be pathogenic. This particular variant has been reported in the literature in an individual with breast or ovarian cancer (PMID: 20616022). This variant is also known as 591G>A and 157Stop in the literature. This sequence change creates a premature translational stop signal at codon 156 (p.Trp156*) of the CDH1 gene. It is expected to result in an absent or disrupted protein product. |